Abstract
This is a transcript from a session held at the Biotechnology Industry Organization 2005 Annual International Convention held in Philadelphia from 19th to 22nd June, 2005, where the authors discussed their experiences and answered questions from the floor. All biotechnology companies can benefit from public funding – small, mid-size and large corporations and non-profits. Examples include funding for applied health research; the BioShield homeland security initiative; and sales to federal, state and local government customers. The panel discussed the basics: (1) where to find money (for example, at NIH, FDA, DOD, DHS, DOE, EPA, via ATP, SBIR and DARPA grants, or from philanthropies such as the Gates Foundation); (2) pros and cons of various approaches to obtaining public funds (via earmarked appropriations, grants, cooperative research agreements, procurement contracts or philanthropy); (3) structuring the deal (allocating liability, intellectual property ownership, deliverables, sharing and commercialising results); and (4) managing the relationship (reporting requirements, follow-on funding).
Article PDF
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gollin, M., Jack, E., Chase, T. et al. Winning the game: Public funds for biotech companies. J Commer Biotechnol 12, 220–228 (2006). https://doi.org/10.1057/palgrave.jcb.3040170
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1057/palgrave.jcb.3040170